Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-Egfr Therapy and Molecularly Selected by Circulating Tumor DNA Analyses

JAMA Oncology - United States
doi 10.1001/jamaoncol.2017.5245
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Medical Association (AMA)

Related search

Circulating Tumor DNA to Monitor Treatment Response and Detect Acquired Resistance in Patients With Metastatic Melanoma

Oncotarget
Oncology
2015English

Emergence of KRAS Mutations and Acquired Resistance to Anti-Egfr Therapy in Colorectal Cancer

Nature
Multidisciplinary
2012English

EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment

JCO Precision Oncology
Cancer ResearchOncology
2018English

Molecular Determinants of Anti-Egfr Sensitivity and Resistance in Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2010English

Early Change in Circulating Tumor DNA as a Potential Predictor of Response to Chemotherapy in Patients With Metastatic Colorectal Cancer

Scientific Reports
Multidisciplinary
2019English

Dermatologic Toxicity Occurring During Anti-Egfr Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Impact of STAT3 Phosphorylation on the Clinical Effectiveness of Anti-EGFR–Based Therapy in Patients With Metastatic Colorectal Cancer

Clinical Colorectal Cancer
OncologyGastroenterology
2013English

KRAS Mutation Analysis of Single Circulating Tumor Cells From Patients With Metastatic Colorectal Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

Change in Circulating Tumor DNA After Hepatic Resection for Metastatic Colorectal Cancer

HPB
HepatologyGastroenterology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy